Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -35

Boston Scientific stock falls as cyberattack prompts guidance cut and BTIG lowers price target

AI-generated analysis

πŸ“‰ Boston Scientific stock dropped roughly 5.9% after the company warned that a cyberattack would cause it to miss Q3 and full-year 2026 guidance for net sales growth and adjusted earnings.

πŸ’» The cybersecurity incident, identified on August 25, 2026, disrupted key IT systems and led to a global interruption of operations affecting the medical device manufacturer.

πŸ“‰ Analyst firm BTIG cut its price target from USD 60.00 to USD 56.00 while retaining a Buy rating due to the uncertainty surrounding the operational disruption.

🏭 Manufacturing has resumed across most global facilities, and major distribution centers are now processing and shipping orders at or above normal operating levels.

βœ… Internal product assessments confirmed no impairment to device function, software code, or physical integrity, ensuring healthcare providers can continue using implants without concern for manufacturing defects.

πŸ“ˆ The consensus 12-month analyst price target remains at USD 71.46, suggesting the stock trades at a significant discount compared to long-term fair value estimates.

πŸ“… Investors expect Boston Scientific to release an updated outlook and Q3 2026 results around October 28, 2026, to clarify the full financial impact of the cyberattack.

Bullish Signals
  • Manufacturing operations have resumed across most of the company's global facilities following the cyber incident.
  • Major distribution centers are currently processing and shipping orders at or above normal operating levels.
  • Product quality analyses confirmed no impairment to device function, software code, or physical integrity of implants.
  • Disruptions affecting remote monitoring activations for certain cardiac devices have been resolved and can resume.
  • Rigorous quality audits verified complete product sterility, allowing healthcare providers to continue using consumables without concern over manufacturing defects.
Risk Factors
  • The company warned that a cyberattack will prevent it from meeting its previously issued guidance for Q3 and full-year 2026 net sales growth and adjusted earnings per share.
  • Analyst firm BTIG lowered its price target from USD 60.00 to USD 56.00 in response to the operational disruption caused by the cybersecurity incident.
Full Analysis
Boston Scientific (BSX) shares fell approximately 5.9% on September 9, 2026, after the medical device manufacturer announced that a significant cyberattack would prevent it from meeting its previously issued guidance for the third quarter and full year 2026. The cybersecurity incident, identified on August 25, 2026, disrupted key information technology systems and caused a global interruption of operations, leading the company to withdraw its forecasts for net sales growth and adjusted earnings per share. Following the news, analyst firm BTIG lowered its price target for Boston Scientific from USD 60.00 to USD 56.00 while maintaining a Buy rating, reflecting increased caution regarding near-term performance. Despite this specific downgrade, the broader analyst consensus remains bullish, with an average 12-month price target of USD 71.46, implying substantial upside potential from the current trading levels around USD 44.98. Operational recovery efforts are underway, with major distribution centers processing orders at normal levels and manufacturing resuming across most global facilities. The company confirmed that product quality analyses found no impairment to device function or physical integrity, resolving disruptions to remote monitoring activations for certain cardiac devices. Investors await the Q3 2026 earnings update expected in late October for further clarity on the financial impact of the incident.